

Giorgio Walter Canonica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1661241/publications.pdf>

Version: 2024-02-01

465
papers

25,084
citations

8181

76
h-index

10734

138
g-index

476
all docs

476
docs citations

476
times ranked

14807
citing authors

#	ARTICLE	IF	CITATIONS
1	Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 150-161.	5.7	35
2	Implementation of the MASK-Air [®] App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study. <i>International Archives of Allergy and Immunology</i> , 2022, 183, 45-50.	2.1	11
3	Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. <i>Journal of Asthma</i> , 2022, 59, 1908-1913.	1.7	4
4	Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID [®] ERD: Results from two randomized placebo [®] controlled phase 3 trials. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1231-1244.	5.7	45
5	Rhinitis and Asthma Patient Perspective [®] (RAPP): Clinical Utility and Predictive Value. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 846-852.e1.	3.8	3
6	Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. <i>Biomedicines</i> , 2022, 10, 200.	3.2	8
7	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	3.8	22
8	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. <i>Journal of Asthma</i> , 2022, 59, 2201-2217.	1.7	18
9	Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?. <i>Frontiers in Allergy</i> , 2022, 3, 854080.	2.8	3
10	Allergen immunotherapy in MASK [®] Air users in real [®] life: Results of a Bayesian mixed [®] effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
11	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK [®] Air [®] real [®] world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
12	The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. <i>ERJ Open Research</i> , 2022, 8, 00065-2022.	2.6	3
13	Disease-modifying anti-asthmatic drugs. <i>Lancet, The</i> , 2022, 399, 1664-1668.	13.7	42
14	Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3084-3095.	5.7	13
15	Local nasal immunotherapy for allergic rhinitis: A systematic review and meta [®] analysis. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1503-1516.	2.8	10
16	Comparison of rhinitis treatments using <sc>MASK</sc> [®] Air [®] data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
17	Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. <i>Frontiers in Allergy</i> , 2022, 3, .	2.8	9
18	Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement. <i>Journal of Personalized Medicine</i> , 2022, 12, 846.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Comorbid allergic rhinitis and asthma: important clinical considerations. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 747-758.	3.0	12
20	Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1562-1565.	2.8	4
21	Biologics in severe asthma: the role of real-world evidence from registries. <i>European Respiratory Review</i> , 2022, 31, 210278.	7.1	13
22	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	5.7	156
23	COVIDâ€™19 pandemic: Practical considerations on the organization of an allergy clinicâ€”An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
24	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
25	ARIAâ€™EAACI statement on asthma and COVIDâ€™19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	5.7	57
26	COVIDâ€™19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 887-892.	5.7	69
27	Spices to Control COVID-19 Symptoms: Yes, but Not Onlyâ€™. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 489-495.	2.1	23
28	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 871-881.	5.6	65
29	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 419-424.	2.5	9
30	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1041-1052.	5.7	38
31	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 324-338.	2.1	33
32	Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110425.	2.6	7
33	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	3.5	14
34	Efficacy and safety of treatment with biologics for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
35	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	10.7	102
36	Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2680-2688.e7.	3.8	50

#	ARTICLE	IF	CITATIONS
37	One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational Study. <i>International Journal of COPD</i> , 2021, Volume 16, 1007-1020.	2.3	0
38	Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1057-1060.	2.5	7
39	Overcoming Barriers to the Effective Management of Severe Asthma in Italy. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 481-491.	3.4	2
40	One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1791-1803.	3.8	23
41	Prof. Mario Sánchez Borges: An enduring legacy and a life well-lived. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1948-1949.	5.7	0
42	Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital. <i>World Allergy Organization Journal</i> , 2021, 14, 100541.	3.5	20
43	The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. <i>World Allergy Organization Journal</i> , 2021, 14, 100533.	3.5	33
44	Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence Assessment Tool. An EAACI methodology committee analysis. <i>Clinical and Translational Allergy</i> , 2021, 11, e12033.	3.2	10
45	ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	5.7	66
46	Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2133-2148.	2.3	0
47	Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3212-3214.	5.7	14
48	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004605.	6.7	10
49	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4353-4370.	3.8	12
50	A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM). <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1019-1031.	3.4	11
51	Allergen immunotherapy: The growing role of observational and randomized trial – Real-World Evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2663-2672.	5.7	39
52	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.8	109
53	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
54	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 219.	2.9	31

#	ARTICLE	IF	CITATIONS
55	Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. <i>Clinical and Translational Allergy</i> , 2021, 11, e12067.	3.2	7
56	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. <i>European Respiratory Journal</i> , 2021, 58, 2102168.	6.7	8
57	WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways. <i>World Allergy Organization Journal</i> , 2021, 14, 100617.	3.5	8
58	30 years of sublingual immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1107-1120.	5.7	41
59	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 163-172.	2.5	7
60	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.8	38
61	Characterization of Severe Asthma Worldwide. <i>Chest</i> , 2020, 157, 790-804.	0.8	165
62	Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3587-3589.	3.8	13
63	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	3.5	30
64	Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 261-267.	2.3	6
65	<p>Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 599-604.	3.4	8
66	Allergic rhinitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 95.	30.5	331
67	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	2.4	6
68	Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma. <i>Respiratory Medicine</i> , 2020, 174, 106199.	2.9	11
69	Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000151.	6.7	84
70	Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study. <i>World Allergy Organization Journal</i> , 2020, 13, 100095.	3.5	16
71	Managing Allergic Rhinitis in the Pharmacy: An ARIA Guide for Implementation in Practice. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 85.	1.6	16
72	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1283-1286.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2920-2936.e1.	3.8	14
74	Minimal clinically important difference for asthma endpoints: an expert consensus report. <i>European Respiratory Review</i> , 2020, 29, 190137.	7.1	72
75	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
76	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€”Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	5.7	67
77	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIAâ€”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114
78	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. <i>World Allergy Organization Journal</i> , 2020, 13, 100080.	3.5	245
79	Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. <i>Clinical and Translational Allergy</i> , 2020, 10, 25.	3.2	20
80	Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model. <i>Clinical and Translational Allergy</i> , 2020, 10, 23.	3.2	21
81	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. <i>Respiratory Medicine</i> , 2020, 171, 106080.	2.9	28
82	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIAâ€”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
83	An academic allergy unit during COVID-19 pandemic in Italy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 227.	2.9	23
84	Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1813-1815.	5.7	28
85	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. <i>Respiratory Medicine</i> , 2020, 166, 105947.	2.9	55
86	Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163.	6.7	56
87	COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. <i>Minerva Medica</i> , 2020, 111, 308-314.	0.9	45
88	COVID-19 Pandemicâ€”Allergen-specific Immunotherapy Positioning in Respiratory Allergy. <i>US Respiratory & Pulmonary Diseases</i> , 2020, 5, 10.	0.2	0
89	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 951-958.	3.0	20
90	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from <i>in vitro</i> allergen-release data. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 921-928.	3.0	7

#	ARTICLE	IF	CITATIONS
91	Asthma from immune pathogenesis to precision medicine. <i>Seminars in Immunology</i> , 2019, 46, 101294.	5.6	35
92	Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 65.	2.0	39
93	Clinically relevant effect of rupatadine 20Âmg and 10Âmg in seasonal allergic rhinitis: a pooled responder analysis. <i>Clinical and Translational Allergy</i> , 2019, 9, 50.	3.2	5
94	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	1.4	11
95	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. <i>Lancet, The</i> , 2019, 394, 1638-1650.	13.7	812
96	One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836.	2.6	57
97	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
98	New drugs in early-stage clinical trials for allergic rhinitis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 267-273.	4.1	13
99	Responders and nonresponders to pharmacotherapy and allergen immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2896-2902.	3.3	7
100	EUFOREA consensus on biologics for CRSwNP with or without asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2312-2319.	5.7	239
101	Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661984127.	2.6	29
102	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
103	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. <i>World Allergy Organization Journal</i> , 2019, 12, 100007.	3.5	82
104	Microarray Immunodiagnostics for Aeroallergens. <i>Current Allergy and Asthma Reports</i> , 2019, 19, 10.	5.3	2
105	The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group. <i>European Respiratory Journal</i> , 2019, 54, 1901511.	6.7	53
106	Treatable traits in chronic rhinosinusitis with nasal polyps. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 373-378.	2.3	14
107	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€; <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
108	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 87-89.	2.6	15

#	ARTICLE	IF	CITATIONS
109	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	3.8	112
110	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
111	Strategies to reduce corticosteroid-related adverse events in asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 61-67.	2.3	28
112	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 113-120.	3.3	14
113	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	3.8	39
114	Sex in Respiratory and Skin Allergies. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 322-332.	6.5	42
115	Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <sc>ASSURE</sc> & <sc>CSU</sc>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1724-1734.	5.7	74
116	Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 776-781.	3.8	118
117	Current insights in allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 152-154.	1.0	20
118	Patient-reported outcomes in asthma clinical trials. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 70-77.	2.6	15
119	Asthma: personalized and precision medicine. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 51-58.	2.3	57
120	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 208-218.	3.8	13
121	Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. <i>World Allergy Organization Journal</i> , 2018, 11, 33.	3.5	25
122	The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials. <i>World Allergy Organization Journal</i> , 2018, 11, 34.	3.5	36
123	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	42
124	The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. <i>European Respiratory Journal</i> , 2018, 52, 1801671.	6.7	28
125	A Charter to Improve Patient Care in Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 1485-1496.	2.9	59
126	Personalizing the approach to asthma treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 299-304.	0.7	3

#	ARTICLE	IF	CITATIONS
127	Omaliuzumab chronic spontaneous urticaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 474-478.	1.0	38
128	Type 2 immunity in asthma. <i>World Allergy Organization Journal</i> , 2018, 11, 13.	3.5	116
129	Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 133-145.	0.2	25
130	A critical appraisal on AIT in childhood asthma. <i>Clinical and Molecular Allergy</i> , 2018, 16, 6.	1.8	8
131	Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 731-737.	3.0	29
132	Is allergic sensitization relevant in severe asthma? Which allergens may be culprits?. <i>World Allergy Organization Journal</i> , 2017, 10, 2.	3.5	28
133	Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. <i>Clinical and Molecular Allergy</i> , 2017, 15, 2.	1.8	27
134	Umeclidinium for the treatment of uncontrolled asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 761-766.	4.1	7
135	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 95-100.	2.6	59
136	Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change?. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 41-52.	2.9	25
137	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€”2016 revision. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 950-958.	2.9	1,199
138	The burden of chronic spontaneous urticaria is substantial: Realâ€”world evidence from <sc>ASSURE</sc>â€”<sc>CSU</sc>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 2005-2016.	5.7	197
139	Targeting Interleukin-5 or Interleukin-5R α : Safety Considerations. <i>Drug Safety</i> , 2017, 40, 559-570.	3.2	22
140	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 83-87.	2.6	11
141	Economic analysis of the phase III MENSEA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 121-131.	1.4	16
142	The role of the pharmacy in the management of bronchial asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 161-165.	1.0	10
143	The year in review: The best of 2016 in the Annals. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 4-9.	1.0	1
144	Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 453-459.	2.3	15

#	ARTICLE	IF	CITATIONS
145	The era of research collaborations: new models for working together. <i>European Respiratory Journal</i> , 2017, 49, 1601848.	6.7	11
146	Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. <i>Clinical and Translational Allergy</i> , 2017, 7, 6.	3.2	55
147	International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. <i>World Allergy Organization Journal</i> , 2017, 10, 14.	3.5	80
148	Rhinitis: adherence to treatment and new technologies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 23-27.	2.3	13
149	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 40-45.	2.6	27
150	Local Side Effects of Sublingual and Oral Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 13-21.	3.8	36
151	Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1158-1166.	2.9	32
152	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. <i>Frontiers in Immunology</i> , 2017, 8, 242.	4.8	37
153	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. <i>Frontiers in Medicine</i> , 2017, 4, 135.	2.6	65
154	Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. <i>Clinical and Molecular Allergy</i> , 2017, 15, 19.	1.8	18
155	Personalized Medicine in Allergy. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 15.	2.9	40
156	Targeted therapy in severe asthma today: focus on immunoglobulin E. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1979-1987.	4.3	38
157	New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 378-383.	1.6	1
158	Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. <i>Journal of Thoracic Disease</i> , 2016, 8, E716-E725.	1.4	12
159	Biosimilars in allergic diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 68-73.	2.3	11
160	The path to personalized medicine in asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 957-965.	2.5	10
161	Update on immunotherapy for the treatment of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 18-24.	2.6	15
162	SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 92-104.	2.2	15

#	ARTICLE	IF	CITATIONS
163	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 88.	5.3	29
164	Therapeutic interventions in severe asthma. <i>World Allergy Organization Journal</i> , 2016, 9, 40.	3.5	38
165	Fatal asthma; is it still an epidemic?. <i>World Allergy Organization Journal</i> , 2016, 9, 42.	3.5	27
166	Molecular diagnosis and precision medicine in allergy management. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1705-1714.	2.3	20
167	The safety of monoclonal antibodies in asthma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1087-1095.	2.4	8
168	The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic model. <i>Journal of Asthma</i> , 2016, 53, 665-667.	1.7	8
169	Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 186-200.	2.3	152
170	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
171	Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 835-846.	3.8	64
172	Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. <i>European Journal of Internal Medicine</i> , 2016, 34, 85-88.	2.2	3
173	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 122-131.	2.1	164
174	The role of interleukin 5 in asthma. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 903-905.	3.0	23
175	Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. <i>New England Journal of Medicine</i> , 2016, 375, 850-860.	27.0	96
176	Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. <i>Human Immunology</i> , 2016, 77, 1172-1178.	2.4	8
177	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1435-1441.	3.1	1
178	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. <i>World Allergy Organization Journal</i> , 2016, 9, 33.	3.5	87
179	Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). <i>World Allergy Organization Journal</i> , 2016, 9, 37.	3.5	30
180	Local allergic rhinitis: entropy or spontaneous response?. <i>World Allergy Organization Journal</i> , 2016, 9, 39.	3.5	23

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. Expert Review of Clinical Immunology, 2016, 12, 805-815.	3.0	12
182	Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respiratory Medicine, 2016, 115, 7-12.	2.9	16
183	Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects. Clinical and Molecular Allergy, 2016, 14, 5.	1.8	1
184	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. World Allergy Organization Journal, 2016, 9, 10.	3.5	123
185	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D. World Allergy Organization Journal, 2016, 9, 17.	3.5	37
186	CD4+CD25highCD127- regulatory T-cells in COPD: smoke and drugs effect. World Allergy Organization Journal, 2016, 9, 5.	3.5	23
187	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Review of Respiratory Medicine, 2016, 10, 29-38.	2.5	27
188	Genuair® Usability Test: Results of a National Public Survey of the Elderly. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 367-371.	1.6	17
189	Allergen Immunotherapy. Immunology and Allergy Clinics of North America, 2016, 36, 1-12.	1.9	43
190	Pidotimod: the state of art. Clinical and Molecular Allergy, 2015, 13, 8.	1.8	37
191	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clinical and Translational Allergy, 2015, 5, 39.	3.2	82
192	Catching allergy by a simple questionnaire. World Allergy Organization Journal, 2015, 8, 16.	3.5	10
193	The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Research and Practice, 2015, 1, 4.	2.4	21
194	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clinical and Translational Allergy, 2015, 5, 36.	3.2	23
195	Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clinical and Molecular Allergy, 2015, 13, 7.	1.8	30
196	The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clinical and Molecular Allergy, 2015, 13, 15.	1.8	14
197	AIT (allergen immunotherapy): a model for the "precision medicine". Clinical and Molecular Allergy, 2015, 13, 24.	1.8	26
198	360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. Clinical and Molecular Allergy, 2015, 13, 25.	1.8	34

#	ARTICLE	IF	CITATIONS
199	Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). <i>Clinical and Molecular Allergy</i> , 2015, 13, 28.	1.8	5
200	Allergen immunotherapy on the way to product-based evaluation—a WAO statement. <i>World Allergy Organization Journal</i> , 2015, 8, 29.	3.5	70
201	Allergen immunotherapy in asthma; what is new?. <i>Asthma Research and Practice</i> , 2015, 1, 6.	2.4	10
202	The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?. <i>Asthma Research and Practice</i> , 2015, 1, 15.	2.4	6
203	Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 267-271.	2.3	33
204	Switching treatments in COPD: implications for costs and treatment adherence. <i>International Journal of COPD</i> , 2015, 10, 2601.	2.3	30
205	Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial. <i>PLoS ONE</i> , 2015, 10, e0118241.	2.5	38
206	European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars. <i>Clinical and Molecular Allergy</i> , 2015, 13, 3.	1.8	1
207	Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA — an observational, 2 phase, patient reported outcomes study. <i>Clinical and Molecular Allergy</i> , 2015, 13, 10.	1.8	9
208	A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. <i>Therapeutic Delivery</i> , 2015, 6, 653-659.	2.2	9
209	Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 309-319.	1.4	52
210	The relationship between allergen immunotherapy and omalizumab for treating asthma. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 129-134.	2.5	17
211	SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 134-140.e1.	1.0	84
212	Clinical Characteristics Associated with Conjunctival Inflammation in Allergic Rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 387-391.e1.	3.8	10
213	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. <i>World Allergy Organization Journal</i> , 2015, 8, 4.	3.5	332
214	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	1.8	28
215	Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR). <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 34, 25-30.	2.6	27
216	Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 233-245.	3.0	17

#	ARTICLE	IF	CITATIONS
217	Public awareness on cystic fibrosis: results from a national pragmatic survey. <i>European Respiratory Journal</i> , 2015, 46, 264-267.	6.7	8
218	Sublingual immunotherapy: focus on tablets. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 4-9.	1.0	14
219	Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 33, 75-80.	2.6	19
220	Disability in Moderate Chronic Obstructive Pulmonary Disease: Prevalence, Burden and Assessment - Results from a Real-Life Study. <i>Respiration</i> , 2015, 89, 100-106.	2.6	11
221	Year in review: allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 173-174.	1.0	3
222	Bilastine: new insight into antihistamine treatment. <i>Clinical and Molecular Allergy</i> , 2015, 13, 1.	1.8	47
223	The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners. <i>Clinical and Molecular Allergy</i> , 2015, 13, 4.	1.8	7
224	The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). <i>World Allergy Organization Journal</i> , 2015, 8, 10.	3.5	38
225	Adherence to asthma treatments. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 49-55.	2.3	28
226	Psychological aspects in asthma: do psychological factors affect asthma management?. <i>Asthma Research and Practice</i> , 2015, 1, 7.	2.4	49
227	ASSURE: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. <i>Clinical and Translational Allergy</i> , 2015, 5, 29.	3.2	45
228	A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 34, 31-36.	2.6	3
229	Escaping the trap of allergic rhinitis. <i>Clinical and Molecular Allergy</i> , 2015, 13, 17.	1.8	7
230	Biomarkers and severe asthma: a critical appraisal. <i>Clinical and Molecular Allergy</i> , 2015, 13, 20.	1.8	49
231	Emerging drugs for allergic conjunctivitis. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 291-302.	2.4	18
232	Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. <i>Immunology Letters</i> , 2014, 162, 2-10.	2.5	95
233	Letter to the Editor. <i>Current Medical Research and Opinion</i> , 2014, 30, 207-209.	1.9	0
234	Sleep Apnea Risk in Subjects With Asthma With or Without Comorbid Rhinitis. <i>Respiratory Care</i> , 2014, 59, 1851-1856.	1.6	21

#	ARTICLE	IF	CITATIONS
235	Cross-sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. <i>Pediatric Allergy and Immunology</i> , 2014, 25, 473-480.	2.6	13
236	Novel <i>in silico</i> technology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1559-1561.	3.0	7
237	RHINASTHMA Adolescents: a new quality of life tool for patients with respiratory allergy. <i>Pediatric Allergy and Immunology</i> , 2014, 25, 450-455.	2.6	20
238	An update on allergen immunotherapy and asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 109-117.	2.6	29
239	The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial. <i>Immunology Letters</i> , 2014, 162, 185-193.	2.5	14
240	Asthma in the elderly: what we know and what we have yet to know. <i>World Allergy Organization Journal</i> , 2014, 7, 8.	3.5	105
241	The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 27, 109-113.	2.6	18
242	Macrogol hypersensitivity reactions during cleansing preparation for colon endoscopy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 353-354.	3.8	20
243	New Therapies for Allergic Rhinitis. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 422.	5.3	17
244	Eligibility for treatment with omalizumab in Italy and Germany. <i>Respiratory Medicine</i> , 2014, 108, 50-56.	2.9	16
245	Potential benefit of omalizumab in respiratory diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 513-519.	1.0	14
246	Biomarker discovery in asthma and COPD by proteomic approaches. <i>Proteomics - Clinical Applications</i> , 2014, 8, 901-915.	1.6	21
247	Pharmacotherapy of allergic rhinitis: current options and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 73-83.	1.8	22
248	Allergenius, an expert system for the interpretation of allergen microarray results. <i>World Allergy Organization Journal</i> , 2014, 7, 15.	3.5	32
249	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. <i>World Allergy Organization Journal</i> , 2014, 7, 6.	3.5	395
250	Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 568-575.e7.	2.9	236
251	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. <i>Allergy and Asthma Proceedings</i> , 2014, 35, 43-46.	2.2	6
252	Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. <i>Drugs of Today</i> , 2014, 50, 15.	1.1	15

#	ARTICLE	IF	CITATIONS
253	Seeking allergy when it hides: which are the best fitting tests?. World Allergy Organization Journal, 2013, 6, 11.	3.5	23
254	Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Review of Vaccines, 2013, 12, 639-659.	4.4	17
255	Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD. Respiratory Medicine, 2013, 107, 1465-1480.	2.9	17
256	Beta ₂ -agonists for exercise-induced asthma. The Cochrane Library, 2013, , CD003564.	2.8	20
257	Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144
258	Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respiratory Research, 2013, 14, 94.	3.6	20
259	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	5.3	5
260	A WAO - ARIA - GA ² LEN consensus document on molecular-based allergy diagnostics. World Allergy Organization Journal, 2013, 6, 17.	3.5	352
261	Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: A survey. Respiratory Medicine, 2013, 107, 361-367.	2.9	23
262	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	1.0	20
263	Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunology Letters, 2013, 149, 62-67.	2.5	19
264	Sublingual Immunotherapy: Recent Advances. Allergology International, 2013, 62, 415-423.	3.3	17
265	Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy, 2013, 5, 257-264.	2.0	24
266	Is Health-Related Quality of Life Associated with Upper and Lower Airway Inflammation in Asthmatics?. BioMed Research International, 2013, 2013, 1-7.	1.9	3
267	Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 446-451.	2.3	24
268	Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 656-662.	2.3	30
269	Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. International Archives of Allergy and Immunology, 2013, 161, 369-377.	2.1	104
270	100 Years of Immunotherapy: The Monaco Charter. International Archives of Allergy and Immunology, 2013, 160, 346-349.	2.1	12

#	ARTICLE	IF	CITATIONS
271	Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. <i>Current Medical Research and Opinion</i> , 2013, 29, 1539-1551.	1.9	27
272	Randomized controlled trial of desloratadine for persistent allergic rhinitis: Correlations between symptom improvement and quality of life. <i>Allergy and Asthma Proceedings</i> , 2013, 34, 274-282.	2.2	17
273	Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. <i>Acta Dermato-Venereologica</i> , 2012, 92, 419-425.	1.3	36
274	Evidences of efficacy of allergen immunotherapy in atopic dermatitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 427-433.	2.3	33
275	The added value of allergen microarray technique to the management of poly-sensitized allergic patients. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 434-439.	2.3	25
276	Allergens and bacteria interaction in the induction of basophil activation. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 164-170.	2.3	6
277	Asthma: developments in targeted therapy. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 13-15.	3.0	5
278	Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. <i>Current Medical Research and Opinion</i> , 2012, 28, 131-139.	1.9	35
279	Allergic diseases and asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 39-41.	2.3	154
280	Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 450-458.	2.2	26
281	Review of Desloratadine Data Using the ARIA Guidelines. <i>World Allergy Organization Journal</i> , 2012, 5, S6-S13.	3.5	2
282	Review of Desloratadine Data Using the ARIA Guidelines. <i>World Allergy Organization Journal</i> , 2012, 5, S6-S13.	3.5	3
283	Latex immunotherapy: state of the art. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 160-165.	1.0	33
284	The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 30-33.	1.0	5
285	Immunotherapy in polysensitized patients: new chances for the allergists?. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 392-394.	1.0	11
286	Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. <i>World Allergy Organization Journal</i> , 2012, 5, 125-147.	3.5	150
287	Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 879-886.	0.8	1
288	Coping with asthma: Is the physician able to identify patient's behaviour?. <i>Respiratory Medicine</i> , 2012, 106, 1625-1630.	2.9	8

#	ARTICLE	IF	CITATIONS
289	Clinical and cytologic characteristics of allergic rhinitis in elderly patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 141-144.	1.0	24
290	Molecular allergy diagnosis: we need to become more knowledgeable. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 387.	1.0	9
291	Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10. <i>PLoS ONE</i> , 2012, 7, e37980.	2.5	11
292	Cochrane Review: Sublingual immunotherapy for treating allergic conjunctivitis. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2012, 7, 1041-1154.	2.0	2
293	The IgE repertoire in children and adolescents resolved at component level: A cross-sectional study. <i>Pediatric Allergy and Immunology</i> , 2012, 23, 433-440.	2.6	59
294	SIT: efficacy depends on product, not on route of application. <i>Pediatric Allergy and Immunology</i> , 2012, 23, 401-401.	2.6	11
295	Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life?. <i>PLoS ONE</i> , 2012, 7, e31178.	2.5	19
296	A review of the use of fluticasone furoate since its launch. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2107-2117.	1.8	14
297	Pitfalls in Respiratory Allergy Management: Alexithymia and Its Impact on Patient-Reported Outcomes. <i>Journal of Asthma</i> , 2011, 48, 25-32.	1.7	20
298	The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 407-411.	1.0	20
299	Sublingual Immunotherapy for Allergic Respiratory Diseases: Efficacy and Safety. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 265-277.	1.9	11
300	Quality of Life in Duchenne Muscular Dystrophy: The Subjective Impact on Children and Parents. <i>Journal of Child Neurology</i> , 2011, 26, 707-713.	1.4	69
301	Sublingual Immunotherapy: Other Indications. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 279-287.	1.9	12
302	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: AAGlobal Allergy and Asthma European Network (GA2LEN) article. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 49-56.e11.	2.9	42
303	Disease-modifying effect and economic implications of sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 44-45.	2.9	26
304	Formoterol by Pressurized Metered-Dose Aerosol or Dry Powder on Airway Obstruction and Lung Hyperinflation in Partially Reversible COPD. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2011, 24, 235-243.	1.4	5
305	Persistent Allergic Rhinitis and the XPERT Study. <i>World Allergy Organization Journal</i> , 2011, 4, S32-S36.	3.5	6
306	Sublingual immunotherapy for allergic rhinitis: an update. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2011, 19, 43-47.	1.8	7

#	ARTICLE	IF	CITATIONS
307	Towards the Grade of Recommendations, Assessment, Development and Evaluation system. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 361-374.	2.3	6
308	Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: a Review of the Evidence. <i>World Allergy Organization Journal</i> , 2011, 4, 47-53.	3.5	54
309	History of the World Allergy Organization: Innovation in Continuity 2008-2009. <i>World Allergy Organization Journal</i> , 2011, 4, 188-192.	3.5	6
310	Persistent Allergic Rhinitis and the XPERT Study. <i>World Allergy Organization Journal</i> , 2011, 4, S32-S36.	3.5	6
311	DRACMA one year after: Which changes have occurred in diagnosis and treatment of CMA in Italy?. <i>Italian Journal of Pediatrics</i> , 2011, 37, 53.	2.6	5
312	The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. <i>Clinical Biochemistry</i> , 2011, 44, 1005-1011.	1.9	91
313	Disability in COPD and its relationship to clinical and patient-reported outcomes. <i>Current Medical Research and Opinion</i> , 2011, 27, 981-986.	1.9	34
314	The Effect of Intranasal Corticosteroids on Asthma Control and Quality of Life in Allergic Rhinitis with Mild Asthma. <i>Journal of Asthma</i> , 2011, 48, 41-47.	1.7	27
315	Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. <i>Journal of Medical Economics</i> , 2011, 14, 305-314.	2.1	61
316	Chronic Obstructive Pulmonary Disease Patient Well-Being and Its Relationship with Clinical and Patient-Reported Outcomes: A Real-Life Observational Study. <i>Respiration</i> , 2011, 82, 335-340.	2.6	6
317	Impact of Bariatric Surgery on Pulmonary Function and Nitric Oxide in Asthmatic and Non-Asthmatic Obese Patients. <i>Journal of Asthma</i> , 2011, 48, 553-557.	1.7	21
318	Asthma Management Failure: A Flaw in Physicians' Behavior or in Patients' Knowledge?. <i>Journal of Asthma</i> , 2011, 48, 266-274.	1.7	20
319	The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009. <i>World Allergy Organization Journal</i> , 2010, 3, S1-S16.	3.5	3
320	Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy. <i>World Allergy Organization Journal</i> , 2010, 3, 31-37.	3.5	0
321	Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. <i>World Allergy Organization Journal</i> , 2010, 3, 216-219.	3.5	18
322	Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy. <i>Clinical and Molecular Allergy</i> , 2010, 8, 4.	1.8	14
323	GA ² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1525-1530.	5.7	185
324	Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA ² LEN Study. <i>International Archives of Allergy and Immunology</i> , 2010, 153, 395-402.	2.1	51

#	ARTICLE	IF	CITATIONS
325	The link between allergic rhinitis and asthma: the united airways disease. Expert Review of Clinical Immunology, 2010, 6, 413-423.	3.0	145
326	Investigational drugs for allergic rhinitis. Expert Opinion on Investigational Drugs, 2010, 19, 93-103.	4.1	6
327	Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Annals of Allergy, Asthma and Immunology, 2010, 105, 223-227.	1.0	46
328	Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Annals of Allergy, Asthma and Immunology, 2010, 104, 215-222.	1.0	141
329	Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2010, 105, 382-386.	1.0	38
330	Considerations about the evaluation of the SLIT meta-analyses. Journal of Allergy and Clinical Immunology, 2010, 125, 509.	2.9	6
331	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	2.9	95
332	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. Journal of Allergy and Clinical Immunology, 2010, 126, 466-476.	2.9	1,322
333	Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology, 2010, 126, 969-975.	2.9	312
334	Emerging sublingual immunotherapy drugs. Expert Opinion on Pharmacotherapy, 2010, 11, 2963-2972.	1.8	2
335	Impact of Urticaria: QOL and Performance. , 2010, , 33-36.		2
336	Why do doctors and patients not follow guidelines?. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 228-233.	2.3	119
337	Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. International Immunology, 2009, 21, 779-791.	4.0	61
338	EAACI/GA ² LEN/EDF/WAO guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1427-1443.	5.7	502
339	EAACI/GA ² LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1417-1426.	5.7	582
340	Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
341	Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. Respiratory Medicine, 2009, 103, 866-872.	2.9	30
342	Feasibility and validation of telespirometry in general practice: The Italian "Alliance" study. Respiratory Medicine, 2009, 103, 1732-1737.	2.9	32

#	ARTICLE	IF	CITATIONS
343	Serum cytotoxic T lymphocyte-associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 258-260.	2.9	8
344	Unmet needs in severe chronic upper airway disease (SCUAD). <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 428-433.	2.9	191
345	Recommendations for appropriate sublingual immunotherapy clinical trials. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 665-670.	2.9	77
346	Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 102, 22-28.	1.0	82
347	Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 102, 69-75.	1.0	44
348	Levocetirizine in the treatment of allergic diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2367-2377.	1.8	2
349	Sublingual immunotherapy: where do we stand? Present and future. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 1-3.	2.3	11
350	Preface - a new section for our Journal - "Perspectives". <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 378.	2.3	0
351	When Allergic Rhinitis is not Only Allergic. <i>American Journal of Rhinology and Allergy</i> , 2009, 23, 312-315.	2.0	27
352	Sub-Lingual Immunotherapy. <i>World Allergy Organization Journal</i> , 2009, 2, 233-281.	3.5	100
353	Advances in Allergen-Specific Immunotherapy. <i>Current Drug Targets</i> , 2009, 10, 1255-1262.	2.1	10
354	Evidence of adherence to allergen-specific immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 544-548.	2.3	78
355	Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: Part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA ² /FN. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 387-403.	5.7	275
356	Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA ² /LEN*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 492-505.	5.7	98
357	Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. <i>Chest</i> , 2008, 133, 599-609.	0.8	263
358	Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 479-485.	2.9	58
359	The role of Pneumococcal vaccine. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 608-615.	2.6	21
360	Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 304-310.	1.0	53

#	ARTICLE	IF	CITATIONS
361	Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 206-211.	1.0	213
362	The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 370-374.	1.0	9
363	Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2829-2839.	1.9	33
364	Worldwide differences on the concept of control of asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 3-5.	2.6	1
365	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. <i>International Archives of Allergy and Immunology</i> , 2008, 147, 231-234.	2.1	18
366	Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. <i>World Allergy Organization Journal</i> , 2008, 1, 70-72.	3.5	0
367	Patient Perceptions of Allergic Rhinitis and Quality of Life. <i>World Allergy Organization Journal</i> , 2008, 1, 138-144.	3.5	60
368	Using the Congestion Quantifier Seven-Item Test to assess change in patient symptoms and their impact. <i>Allergy and Asthma Proceedings</i> , 2008, 29, 295-303.	2.2	9
369	New insights into airway remodelling in asthma and its possible modulation. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 367-375.	2.3	32
370	Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. <i>New England Journal of Medicine</i> , 2007, 356, 2040-2052.	27.0	320
371	The Safety of Allergen Specific Sublingual Immunotherapy. <i>Current Drug Safety</i> , 2007, 2, 117-123.	0.6	31
372	Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 463-467.	3.0	1
373	Airway remodelling in children: when does it start?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 196-200.	2.3	20
374	Immunotherapy: clinical trials "optimal trial and clinical outcomes. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 561-566.	2.3	25
375	New perspectives in the treatment of allergic rhinitis and asthma in children. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 201-206.	2.3	12
376	Clara cell 16 protein in COPD sputum: A marker of small airways damage?. <i>Respiratory Medicine</i> , 2007, 101, 2119-2124.	2.9	49
377	Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. <i>Journal of Medical Economics</i> , 2007, 10, 285-296.	2.1	30
378	Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 164-170.	2.9	210

#	ARTICLE	IF	CITATIONS
379	Safety Profile of Sublingual Immunotherapy. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 225-234.	1.4	7
380	Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. <i>Allergologia Et Immunopathologia</i> , 2006, 34, 82-83.	1.7	16
381	Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 141-148.	1.0	288
382	Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990â€“1999). <i>Respiratory Medicine</i> , 2006, 100, 1431-1435.	2.9	33
383	Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. <i>Respiratory Medicine</i> , 2006, 100, 1706-1715.	2.9	43
384	Sublingual immunotherapy: update 2006. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2006, 6, 449-454.	2.3	26
385	Local Nasal Specific Immunotherapy for Allergic Rhinitis. <i>Allergy, Asthma and Clinical Immunology</i> , 2006, 2, 117.	2.0	20
386	EAACI/GA²/LEN/EDF guideline: management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 321-331.	5.7	278
387	EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 316-320.	5.7	221
388	Freedom to enjoy life - the ultimate goal in allergy management. <i>Clinical and Experimental Allergy Reviews</i> , 2006, 6, 15-19.	0.3	1
389	New insights in sublingual immunotherapy. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 407-412.	5.3	7
390	Treating Asthma as an Inflammatory Disease. <i>Chest</i> , 2006, 130, 21S-28S.	0.8	51
391	Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. <i>Inflammation and Allergy: Drug Targets</i> , 2006, 5, 43-51.	1.8	11
392	Freedom to enjoy life - the ultimate goal in allergy management. <i>Clinical and Experimental Allergy Reviews</i> , 2006, 6, 15-19.	0.3	1
393	Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of Î±-SMA and NF-Î±B. <i>International Immunology</i> , 2005, 17, 1473-1481.	4.0	44
394	Antiallergic drugs and quality of life. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 437-445.	1.4	2
395	Pharmacokinetics of Der p 2 Allergen and Derived Monomeric Allergoid in Allergic Volunteers. <i>International Archives of Allergy and Immunology</i> , 2005, 138, 197-202.	2.1	56
396	Important Factors to Consider for Patients with Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2005, 40, 1374-1375.	5.8	1

#	ARTICLE	IF	CITATIONS
397	Quality of life and polysensitization in young men with intermittent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 640-643.	1.0	15
398	A model of allergen-driven human airway contraction: β_2 pathway dysfunction without cytokine involvement. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 273-278.	1.0	7
399	A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis. <i>Clinical Therapeutics</i> , 2005, 27, 979-992.	2.5	30
400	New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal. <i>Respiratory Medicine</i> , 2005, 99, 1363-1376.	2.9	17
401	Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1184-1188.	2.9	81
402	World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma. <i>International Archives of Allergy and Immunology</i> , 2004, 135, 83-92.	2.1	64
403	Comparison of the Effects in the Nose and Skin of a Single Dose of Desloratadine and Levocetirizine over 24 Hours. <i>International Archives of Allergy and Immunology</i> , 2004, 135, 143-147.	2.1	29
404	CD40 on Adult Human Airway Epithelial Cells: Expression and Proinflammatory Effects. <i>Journal of Immunology</i> , 2004, 172, 3205-3214.	0.8	25
405	Quantitative assessment of the adherence to sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1219-1220.	2.9	77
406	Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 838-844.	2.9	199
407	Sublingual and oral immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2004, 24, 685-704.	1.9	12
408	Sublingual immunotherapy: what lessons can we draw from recent studies?. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 2004, 44, 584-589.	0.1	1
409	Sublingual immunotherapy: an update. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2004, 4, 31-36.	2.3	28
410	An update on the asthma-rhinitis link. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2004, 4, 177-183.	2.3	48
411	The asthma-rhinitis association: Between the clinical hypothesis and the scientific theory. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 191-193.	5.3	3
412	Requirements for medications commonly used in the treatment of allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 192-197.	5.7	133
413	Medical treatment reverses cytokine pattern in allergic and nonallergic chronic rhinosinusitis in asthmatic children. <i>Pediatric Allergy and Immunology</i> , 2003, 14, 238-241.	2.6	30
414	Clinical and therapeutic aspects of allergic asthma in adolescents. <i>Pediatric Allergy and Immunology</i> , 2003, 14, 453-457.	2.6	12

#	ARTICLE	IF	CITATIONS
415	Effects of fexofenadine and other antihistamines on components of the allergic response. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, S78-S82.	2.9	46
416	Noninjection routes for immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 437-448.	2.9	266
417	Does allergic rhinosinusitis exist?. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 2003, 43, 236-239.	0.1	0
418	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 714-716.	1.2	44
419	Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies. <i>International Archives of Allergy and Immunology</i> , 2003, 132, 1-12.	2.1	48
420	Oral and sublingual immunotherapy in paediatric patients. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2003, 3, 139-145.	2.3	18
421	Single-Dose Oral Tolerance Test with Alternative Compounds for the Management of Adverse Reactions to Drugs. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 242-247.	2.1	12
422	Harmful effect of immunotherapy in children with combined snail and mite allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 627-629.	2.9	71
423	Human lung myofibroblasts as effectors of the inflammatory process: the common receptor $\alpha_5\beta_1$ chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF- α . <i>European Journal of Immunology</i> , 2002, 32, 2437-2449.	2.9	26
424	Underdiagnosis and Undertreatment of Asthma: A 9-Year Study of Italian Conscripts. <i>International Archives of Allergy and Immunology</i> , 2001, 125, 211-215.	2.1	25
425	Antihistamines in the Treatment of Bronchial Asthma. Present Knowledge and Future Perspectives. <i>Pulmonary Pharmacology and Therapeutics</i> , 2001, 14, 267-276.	2.6	14
426	Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. <i>Annals of Allergy, Asthma and Immunology</i> , 2001, 86, 433-438.	1.0	32
427	Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. <i>BioDrugs</i> , 2001, 15, 509-519.	4.6	17
428	The nose-lung interaction in allergic rhinitis and asthma: united airways disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 7-13.	2.3	22
429	Quality of Life in Respiratory Allergy. <i>Allergy and Asthma Proceedings</i> , 2001, 22, 177-181.	2.2	10
430	Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2001, 56, 989-992.	5.7	88
431	Health-related quality of life assessment in young adults with seasonal allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2001, 56, 313-317.	5.7	61
432	Novel Anti-inflammatory Effects of the Inhaled Corticosteroid Fluticasone Propionate During Lung Myofibroblastic Differentiation. <i>Journal of Immunology</i> , 2001, 167, 5329-5337.	0.8	28

#	ARTICLE	IF	CITATIONS
433	Nonsteroidal Antiallergic Treatments in Allergic Rhinitis. American Journal of Rhinology & Allergy, 2000, 14, 319-324.	2.2	5
434	Unconventional medicine: a risk of undertreatment of allergic patients. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1117-1119.	5.7	11
435	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	22
436	Minimal persistent inflammation may be controlled by cetirizine. Annals of Allergy, Asthma and Immunology, 1999, 83, 445-448.	1.0	13
437	Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 1999, 104, 964-968.	2.9	155
438	Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 1999, 104, 425-432.	2.9	206
439	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	2
440	Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet, The, 1998, 351, 629-632.	13.7	252
441	Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge. International Archives of Allergy and Immunology, 1998, 115, 157-161.	2.1	27
442	Allergen-Specific Conjunctival Challenge in Asthma. International Archives of Allergy and Immunology, 1997, 112, 247-250.	2.1	3
443	Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. Journal of Allergy and Clinical Immunology, 1997, 100, 122-129.	2.9	134
444	Continuous Versus On Demand Treatment with Cetirizine for Allergic Rhinitis. Annals of Allergy, Asthma and Immunology, 1997, 79, 507-511.	1.0	62
445	Molecular events in allergic inflammation: experimental models and possible modulation. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 25-30.	5.7	15
446	Management of Allergic Conjunctivitis. BioDrugs, 1996, 5, 374-391.	0.7	13
447	Cetirizine Reduces ICAM-1 on Epithelial Cells during Nasal Minimal Persistent Inflammation in Asymptomatic Children with Mite-Allergic Asthma. International Archives of Allergy and Immunology, 1996, 109, 272-276.	2.1	76
448	Intraepithelial $\gamma\delta$ -Positive T Lymphocytes and Intestinal Villous Atrophy. International Archives of Allergy and Immunology, 1996, 110, 233-237.	2.1	12
449	Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. Journal of Allergy and Clinical Immunology, 1995, 96, 971-979.	2.9	231
450	Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. Journal of Allergy and Clinical Immunology, 1995, 96, 580-587.	2.9	166

#	ARTICLE	IF	CITATIONS
451	Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 95, 612-621.	2.9	136
452	Evidence of intercellular adhesion molecule-1 expression on nasal epithelial cells in acute rhinoconjunctivitis caused by pollen exposure. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 738-746.	2.9	64
453	Drug Treatment of Allergic Conjunctivitis. <i>Drugs</i> , 1992, 43, 154-176.	10.9	58
454	Functional involvement of the LFA-1/ICAM-1 adhesion system in the autologous mixed lymphocyte reaction. <i>Cellular Immunology</i> , 1990, 128, 362-369.	3.0	15
455	Antihistamines in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1989, 44, 114-116.	5.7	1
456	T-LYMPHOCYTE ACTIVATION AND ALLERGY. <i>Lancet, The</i> , 1988, 332, 399.	13.7	0
457	T Cell Activation Surface Markers and Autologous Mixed Lymphocyte Reaction Do Not Differ in True and Pseudo Food Allergy. <i>International Archives of Allergy and Immunology</i> , 1987, 83, 193-197.	2.1	4
458	Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells. <i>International Journal of Cancer</i> , 1987, 39, 703-707.	5.1	1
459	T cell-mediated mechanisms in autoimmune thyroiditis. <i>Immunologic Research</i> , 1986, 5, 305-313.	2.9	6
460	Deficiency of the Autologous Mixed Lymphocyte Reaction in Patients with Autoimmune Thyroid Disease. <i>International Archives of Allergy and Immunology</i> , 1984, 73, 137-140.	2.1	11
461	Circulating T-cell subsets in Graves' disease: Differences between patients with active disease and in remission after ¹³¹ I-therapy. <i>Clinical Immunology and Immunopathology</i> , 1983, 28, 265-271.	2.0	28
462	Abnormalities of Circulating T Cell Subsets in Atopy: Influence of Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 1983, 71, 300-303.	2.1	9
463	Inhibition of autologous mixed lymphocyte reaction by aggregated IgG molecules. <i>European Journal of Immunology</i> , 1982, 12, 687-691.	2.9	12
464	Receptors for Immunoglobulins on Resting and Activated Human T Cells. <i>Immunological Reviews</i> , 1981, 56, 141-162.	6.0	52
465	Human T-Lymphocyte Subpopulations in Hashimoto's Disease*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981, 52, 553-556.	3.6	25